Reuters. Last month, Bharat Biotech had completed the Phase 2/3 trials of Covaxin for use in children under 18 years of age. "Paediatric Covaxin just completed phase 2/3 trials.
The data analysis is going on. We will be submitting the data ( to the regulator) by next week. The number of subjects ( volunteers) is touching 1000," Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella had said.
Meanwhile, the WHO said that it will take a call on granting Emergency Use Listing (EUL) status for Covaxin next week, the global health body said on Tuesday. "WHO & an independent group of experts are scheduled to meet next week to carry out the risk/benefit assessment and come to a final decision whether to grant